At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
|Articles|July 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 7
- Volume 5
- Issue 7
CDC Says Teen Smoking Still Rising
ATLANTA--The Centers for Disease Control and Prevention (CDC) has issued a report stating that teenage smoking has increased from 27.5% of all high school students in 1991 to 34.8% in 1995. And smoking among African-American boys has doubled, from 14.1% in 1991 to 27.8% in 1995.
Advertisement
ATLANTA--The Centers for Disease Control and Prevention (CDC)has issued a report stating that teenage smoking has increasedfrom 27.5% of all high school students in 1991 to 34.8% in 1995.And smoking among African-American boys has doubled, from 14.1%in 1991 to 27.8% in 1995.
Michael Eriksen, director of the CDC's Office on Smoking and Health,said that smoking rates have "gone up for every group exceptfor black teenage girls."
Articles in this issue
over 30 years ago
Princess Diana Helps Raise Over $1 Million for Cancer Researchover 30 years ago
Study Gives Terminal Patients Option: $18,000 or More Treatmentover 30 years ago
Proven: Colorectal Screening Cuts Deaths 50%over 30 years ago
Virtual Colonoscopy Technique Feasible in Detecting Polypsover 30 years ago
Trimetrexate Appears Beneficial in Colorectal Cancerover 30 years ago
FDA Liaison Program Answers Patients' Questions About Trialsover 30 years ago
New Company Joins With RPR To Develop Intrabody Technologyover 30 years ago
More Insurers Covering ABMT, Despite Lack of Efficacy Dataover 30 years ago
ThinPrep Pap Test Offers Improved Slide PreparationAdvertisement
Related to this article
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
2
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
3
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5